DekaBank Deutsche Girozentrale Raises Stock Holdings in Zimmer Biomet Holdings, Inc. $ZBH

DekaBank Deutsche Girozentrale raised its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 0.1% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 276,974 shares of the medical equipment provider’s stock after acquiring an additional 339 shares during the quarter. DekaBank Deutsche Girozentrale owned approximately 0.14% of Zimmer Biomet worth $25,445,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Washington Trust Advisors Inc. acquired a new position in Zimmer Biomet in the 1st quarter valued at about $30,000. Columbia River Financial Group LLC acquired a new position in Zimmer Biomet in the 1st quarter valued at about $30,000. Accent Capital Management LLC acquired a new position in Zimmer Biomet in the 1st quarter valued at about $35,000. Cullen Frost Bankers Inc. grew its position in Zimmer Biomet by 1,452.4% in the 1st quarter. Cullen Frost Bankers Inc. now owns 326 shares of the medical equipment provider’s stock valued at $37,000 after acquiring an additional 305 shares in the last quarter. Finally, Zions Bancorporation National Association UT acquired a new position in Zimmer Biomet in the 1st quarter valued at about $48,000. 88.89% of the stock is owned by institutional investors and hedge funds.

Zimmer Biomet Stock Performance

Shares of ZBH opened at $103.87 on Thursday. The stock has a 50 day moving average price of $101.83 and a 200 day moving average price of $97.72. The company has a quick ratio of 0.96, a current ratio of 1.87 and a debt-to-equity ratio of 0.54. The company has a market capitalization of $20.58 billion, a price-to-earnings ratio of 25.27, a price-to-earnings-growth ratio of 2.36 and a beta of 0.67. Zimmer Biomet Holdings, Inc. has a 52-week low of $89.22 and a 52-week high of $114.72.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.98 by $0.09. The firm had revenue of $2.08 billion during the quarter, compared to the consensus estimate of $2.06 billion. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.The firm’s quarterly revenue was up 7.0% compared to the same quarter last year. During the same period in the prior year, the company posted $2.01 earnings per share. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. Research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be issued a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date of this dividend is Tuesday, September 30th. Zimmer Biomet’s dividend payout ratio is 23.36%.

Analyst Ratings Changes

Several equities analysts have weighed in on the company. Redburn Partners set a $130.00 target price on Zimmer Biomet in a research report on Thursday, September 18th. Evercore ISI lowered their price objective on Zimmer Biomet from $106.00 to $104.00 and set an “in-line” rating for the company in a research report on Tuesday, October 7th. Raymond James Financial boosted their price objective on Zimmer Biomet from $104.00 to $113.00 and gave the stock an “outperform” rating in a research report on Friday, August 8th. UBS Group boosted their price objective on Zimmer Biomet from $91.00 to $96.00 and gave the stock a “sell” rating in a research report on Friday, August 8th. Finally, Rothschild Redb raised Zimmer Biomet to a “strong-buy” rating in a research report on Thursday, September 18th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, eight have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $111.94.

Insider Transactions at Zimmer Biomet

In related news, SVP Lori Winkler sold 1,500 shares of the company’s stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $104.15, for a total value of $156,225.00. Following the completion of the transaction, the senior vice president directly owned 6,833 shares of the company’s stock, valued at $711,656.95. This represents a 18.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.39% of the stock is owned by company insiders.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.